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Objective: Type II endoleak is usually a benign ﬁnding after endovascular abdominal aortic aneurysm repair (EVAR). In
some patients, however, type II endoleak leads to aneurysm sac expansion and the need for further intervention. We
examined which factors, in particular the components of metabolic syndrome (MetS), would lead to an increase risk of
endoleak after EVAR.
Methods: The medical records of all patients who underwent EVAR between 2002 and 2011 at the Veterans Affairs
Connecticut Healthcare System were reviewed. MetS was deﬁned as the presence of three or more of the following:
hypertension (blood pressure $130 mm Hg/$90 mm Hg), serum triglycerides $150 mg/dL, serum high-density
lipoproteins #50 mg/dL for women and #40 mg/dL for men, body mass index $30 kg/m2, and fasting blood
glucose $110 mg/dL. Development of endoleak, including speciﬁc endoleak type, was determined by review of standard
radiologic surveillance.
Results: During a 9-year period, 79 male patients (mean age, 73.5 years), underwent EVAR for infrarenal abdominal
aortic aneurysm (mean 6.2 cm maximal transverse diameter). MetS was present in 52 patients (66%). The distribution of
MetS factors among all patients was hypertension in 86%, hypertriglyceridemia in 72%, decreased high-density lipoprotein
in 68%, diabetes in 37%, and a body mass index of $30 kg/m2 in 30%. No survival difference was found between the
MetS and non-MetS groups (P[ .66). There was no difference in perioperative myocardial infarction or visceral ischemia
immediately postoperatively between the two groups. Patients with MetS had a signiﬁcant increase in acute kidney injury
(n [ 7, P [ .0128). Endoleaks of all types were detected in 26% (n [ 20) of all patients; patients with MetS had more
endoleaks than patients without MetS (35% vs 7.4%, P [ .0039). Of the 19 type II endoleaks, 79% were present at the
time of EVAR and only 21% developed during surveillance; 95% had MetS (P [ .0007).
Conclusions: Type II endoleak after EVAR for abdominal aortic aneurysm is associated with MetS. Whether these patients
are subject to more subsequent intervention due to sac expansion is unclear. MetS may be a factor to consider in the
treatment of type II endoleak. (J Vasc Surg 2014;59:938-43.)Endoleak remains a signiﬁcant concern after endovas-
cular aneurysm repair (EVAR) because persistent blood
ﬂow can cause repressurization and re-expansion of the
excluded aneurysmal sac, with concomitant risk of
rupture.1,2 The primary reason for reintervention after
EVAR continues to be endoleak.3 Type I and III endoleaks
are generally treated urgently to prevent progression to
aneurysm rupture4 and are often attributed to failure ofthe Department of Surgery, Yale University School of Medicine,
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treated more conservatively, but a signiﬁcant percentage
require a secondary intervention to prevent sac expansion
and subsequent rupture.5 However, the factors associated
with endoleak development, especially those that appear
later in long-term follow-up, are not well established.
The metabolic syndrome (MetS) has gained increased
attention recently, especially in the United States, and
correlates with the obesity epidemic.6 MetS is deﬁned as
a constellation of clinical and laboratory risk factors,
including dyslipidemia, deﬁned as low levels of serum
high-density lipoprotein (HDL) and high levels of serum
triglycerides, hypertension, hyperglycemia, and truncal
obesity.7 The syndrome is diagnosed with the presence of
at least three of these ﬁve categories. Each of these meta-
bolic components has an effect on vascular biology and
can be related to various pathophysiologic outcomes.
MetS has been closely associated with adverse cardiovas-
cular and peripheral vascular outcomes,8 including saphe-
nous bypass graft failure9 and arteriovenous ﬁstula10
complications.
We examined the inﬂuence of MetS on outcome after
EVAR, with attention to the factors associated with the
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MetS with other cardiovascular morbidity, we hypothe-
sized that MetS confers an increased risk of adverse peri-
operative outcomes and long-term complications after
EVAR.
METHODS
Study design. The medical records of all patients who
underwent EVAR to treat an abdominal aortic aneurysm
(AAA) at the Veterans Administration Connecticut
Healthcare System (West Haven, Conn) from 2003 to
2011 were retrospectively reviewed. Exclusion criteria
included any patient with a thoracic component to the
AAA, any attempted EVAR that required intraoperative
conversion to an open approach, or when sufﬁcient data
could not be obtained from the electronic record.
Patient demographics, comorbidities, and perioperative
outcomes were reviewed. Data acquired for each patient
included diagnosis of hypertension or active prescription
for antihypertensive medications; serum triglycerides or
diagnosis of hypertriglyceridemia; HDL and total choles-
terol levels; fasting glucose measurements, hemoglobin
A1c, or active prescription for antihyperglycemic medica-
tions; and last recorded height and weight. Other pertinent
history was recorded, including myocardial infarction (MI),
congestive heart failure, atrial ﬁbrillation, cerebrovascular
accident, chronic obstructive pulmonary disease, chronic
kidney disease, dialysis history, cancer history, tobacco
use, alcohol abuse, and the current use of anticoagulation
medication. Perioperative complications included pulmo-
nary (prolonged intubation or need for reintubation),
MI, acute kidney injury (AKI), need for temporary or
permanent dialysis, deep vein thrombosis or pulmonary
embolism, intestinal ischemia, or spinal cord ischemia.
MetS was deﬁned, using modiﬁed National Cholesterol
Education Program and World Health Organization
criteria, as a patient having three or more of the following
criteria: diagnosis of hypertension (systolic blood pressure
>130 mm Hg or diastolic blood pressure >90 mm Hg
on three measurements during at least a 6-month period)
or signiﬁcant pharmacologic antihypertensive medication
use; at least one measured serum triglyceride level
>150 mg/dL and pharmacologic treatment; a low serum
level of HDL measuring <50 mg/dL for women
or <40 mg/dL for men; a fasting blood glucose of
>110 mg/dL or a diagnosis of diabetes requiring pharma-
cologic treatment; and a body mass index (BMI) of
>30 kg/m2 at the time of the intervention.11 The MetS
score was deﬁned as the number of MetS parameters
present in an individual patient and ranges from 0 to 5.
An endovascular approach and the graft type used were
determined by the operative surgeon. Excluder (W. L.
Gore and Associates, Flagstaff, Ariz), AneuRx (Medtronic,
Santa Rosa, Calif), Zenith (Cook, Bloomington, Ind),
Talent (Medtronic), Endologix (Irvine, Calif), Endurant
(Medtronic), and Ancure (Guidant Endovascular Solu-
tions, Menlo Park, Calif) grafts were used during the 9 years
of the study. Perioperative myocardial ischemia wasdetermined by a serum troponin rise above our institution’s
normal range for laboratory values. AKI was deﬁned as
a creatinine rise of 1.5 times baseline or a >0.3 mg/dL
increase above baseline.
Records were examined for long-term follow-up
through September 2012. Patients were monitored with
at least annual imaging, typically computed tomography
(CT) angiograms (CTA), without contrast if the patient
had chronic renal insufﬁciency, and occasionally duplex
ultrasound imaging or magnetic resonance imaging. Endo-
leak was deﬁned using current Society for Vascular Surgery
criteria12 and was documented at the completion intrao-
perative angiography or during routine surveillance.
Variables are listed as mean6 standard deviation. Rates
for comorbidities, complications, and endoleaks were
compared between patients with MetS and without MetS
using c2 and the Fisher exact testing, where appropriate.
Risk factors were multivariately analyzed by logistic regres-
sion analysis. Kaplan-Meier analysis was used to analyze
long-term mortality, and log-rank and Gehan-Breslow-
Wilcoxon analysis were used to compare survival curves.
P values <.05 were considered signiﬁcant. Statistical anal-
ysis was performed using JMP 9.0 software (SAS Institute,
Cary, NC).RESULTS
The study included 79 male patients. Two patients
with thoracic aortic aneurysms and two patients with insuf-
ﬁcient data in the record were excluded. No patients were
converted intraoperatively to open repair. No patients were
treated with complex endografts.
Patients were an average age of 73.5 6 7 years (range,
55-89 years) and 92% Caucasian (Table I). The mean
follow-up time was 2.5 years for the entire cohort,
27.3 months for patients with endoleak, and 26.6 months
for those without endoleak. Patients received an average of
4.1 follow-up images, consisting of 97.2% CT scans and
2.8% ultrasound imaging or magnetic resonance imaging.
Only three patients, all of whom were in the MetS group,
received noncontrast CT scans. One of these patients
underwent magnetic resonance angiography, which
demonstrated a type II endoleak. The remaining two
patients were never determined to have an endoleak.
Only two patients received ultrasound for surveillance
due to chronic renal insufﬁciency; both patients had
MetS and were noted to have stable sac sizes, despite one
patient with persistent type II endoleak.
All patients who underwent EVAR had an infrarenal
AAA with a mean transverse diameter of 6.2 cm preopera-
tively. One AAA was treated emergently for rupture, and
the rest were elective cases. One patient had an aborted
elective open repair 2 months before subsequent EVAR.
Six patients had concurrent aneurysmal dilatation of iliac
vessels, and an internal iliac artery was embolized preoper-
atively in ﬁve patients. No patients underwent preoperative
embolization of inferior mesenteric arteries or lumbar
arteries.
Table I. Patient demographics and comorbidities
Variable
All patients
(N ¼ 79),
MetS
(n ¼ 52),
Non-MetS
(n ¼ 27),
PNo. (%) No. (%) No. (%)
Demographics
Age >70 years 35 (44) 26 (50) 9 (33) .15
Caucasian 73 (92.4) 47 (90.4) 26 (96.3) .37
Male sex 79 (100) 52 (100) 27 (100) NA
Comorbidities
Alcohol usea 9 (11) 6 (12) 3 (11) .95
Atrial ﬁbrillation 12 (15) 8 (15) 4 (15) .95
Anticoagulationb 46 (58) 36 (69) 10 (37) .006c
CHF 9 (11) 6 (12) 3 (11) .95
CKD 21 (27) 16 (31) 5 (19) .23
CVA 13 (16) 9 (17) 4 (15) .78
COPD 21 (27) 14 (27) 7 (26) .92
Dialysisd 3 (4) 2 (4) 1 (4) .97
MIe 24 (30) 19 (37) 5 (19) .09
Smokingf 34 (43) 22 (42) 12 (44) .86
Cancer history 22 (28) 13 (25) 9 (33) .44
CHF, Congestive heart failure; CKD, chronic kidney disease; CVA, cere-
brovascular accident; COPD, chronic obstructive pulmonary disease; MetS,
metabolic syndrome; MI, myocardial infarction; NA, not applicable.
aDeﬁned as >1 drink/d for women or >2 drinks/d for men.
bIncludes aspirin, clopidogrel, or warfarin.
cStatistically signiﬁcant.
dIncludes hemodialysis or peritoneal dialysis.
eHistory of MI or coronary revascularization.
fDeﬁned as >20 pack-year history.
Table II. Components of themetabolic syndrome (MetS)
Variablea
All patients
(N ¼ 79)
MetS
(n ¼ 52)
Non-MetS
(n ¼ 27) Pb
Serum triglyceride
>150 mg/dL
57 (72) 48 (92) 9 (33) <.0001
Serum HDL
cholesterolc
54 (68) 42 (81) 12 (44) .0011
Hypertensiond 68 (86) 48 (92) 20 (74) .0309
Hyperglycemiae 29 (37) 29 (56) 0 (0) <.0001
BMI >30.0 kg/m2 24 (30) 22 (42) 2 (7) .0006
Total MetS score 2.95 6
1.16
3.62 6
0.68
1.58 6
0.58
BMI, Body mass index; HDL, high-density lipoprotein.
aData are shown as number (%) or mean 6 standard deviation.
bAll P values were statistically signiﬁcant.
cDeﬁned as <40 mg/dL for men and <50 mg/dL for women.
dDeﬁned as systolic blood pressure >140 mm Hg or diastolic blood pres-
sure >90 mm Hg.
eDeﬁned as fasting serum glucose >110 mg/dL.
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difference between groups with or without MetS in MI,
congestive heart failure, atrial ﬁbrillation, cerebrovascular
accident, chronic obstructive pulmonary disease, chronic
kidney disease, dialysis history, cancer history, tobacco
use, or alcohol abuse (Table I). The current use of antipla-
telet or anticoagulation therapy, including aspirin, clopi-
dogrel, warfarin, or a combination, was signiﬁcantly
higher in the MetS group than in the non-MetS group
(Table I).
The distribution of MetS factors among all patients was
hypertension in 86%, hypertriglyceridemia in 72%,
decreased HDL in 68%, diabetes in 37%, and a BMI of
$30 kg/m2 in 30%. MetS was diagnosed in 66% of all
patients (Table II). As expected, there was a signiﬁcantly
higher prevalence of each component of MetS in the
patients diagnosed with MetS than in patients without
MetS. The factor most commonly diagnosed in patients
with and without MetS was hypertension, with signiﬁcant
prevalence of elevated serum triglycerides, elevated serum
HDL, elevated fasting serum glucose, and elevated BMI
in patients with MetS (Table II). The MetS scores of the
cohort were distributed normally: score 5, 7.5%; score 4,
26.6%; score 3, 31.7%; score 2, 21.5%; score 1, 11.4%;
score 0, 1.3% (P ¼ .07).
Perioperative outcomes. There were few cardiopul-
monary complications. Five patients required prolonged
intubation or reintubation. One of these patients died of
respiratory failure 38 days after surgery. Four patients had
evidence of perioperative myocardial ischemia butexperienced minimal morbidity and required no invasive
intervention. AKI occurred in seven patients (8.9%) who
sustained a mean creatinine increase of 1.8 mg/dL above
baseline. Only one of these seven patients had pre-
existing chronic kidney disease, and six had normal renal
function (P ¼ .44 by c2). However, all patients with peri-
operative AKI had MetS (P ¼ .0128). Two of the seven
patients with AKI progressed to chronic renal failure
requiring hemodialysis; one of these patients recovered but
one patient required ongoing hemodialysis. Colon
ischemia was identiﬁed in three patients, and all required
surgical intervention; only one of these three patients had
MetS. No patient had spinal cord ischemia, deep venous
thrombosis, or pulmonary embolism postoperatively.
Long-term outcomes. Overall long-term mortality
was 35.4% (n ¼ 28; Fig, A). No patient died of aneurysm-
related disease; the most common cause of death was
cancer. Of the 28 patients who died, 19 (68%) were in the
MetS group vs nine (32%) in the non-MetS group, for
a mortality of 24.1% and 11.4%, respectively (P ¼ .66 by
log-rank test). Kaplan-Meier survival of the overall group,
as well as subgroups of MetS and non-MetS, is seen in Fig,
A and B. Although the survival was similar between
patients with and without MetS (Fig, B), these data were
reanalyzed with the Gehan-Breslow-Wilcoxon test to see if
the early differences in survival were signiﬁcant; even with
this test, there was no statistically signiﬁcant difference
between the groups (P ¼ .12).
Endoleak. Endoleak, whether documented at the
completion angiogram or that developed later during
follow-up, occurred in 26% of patients, with most having
type II endoleaks (Table III); all were type IIA endoleaks.
No difference was seen between the MetS group and the
non-MetS group in the occurrence of type I or type III
endoleaks; however, patients with MetS were signiﬁcantly
more likely to be associated with a type II endoleak
(Table III). There was no signiﬁcance of endoleak devel-
opment among those patients receiving preoperative
Table III. Presence of endoleak by type
Variable
All patients
(N ¼ 79),
MetS
(n ¼ 52),
Non-MetS
(n ¼ 27),
PNo. (%) No. (%) No. (%)
Endoleak (all types) 20 (26) 18 (34) 3 (11) .0039a
Type I 3 (3.8) 2 (3.8) 1 (3.7) .99
Type II 19 (24) 18 (34) 1 (1.3) .0007a
Type III 2 (2.53) 1 (2.5) 1 (3.7) .99
MetS, Metabolic syndrome.
aStatistically signiﬁcant.
Table IV. Univariate analysis of endoleak risk factors
Risk factors
Endoleak, No endoleak,
PNo. (%) No. (%)
Age >75 years 11 (14) 24 (30) .38
Caucasian 20 (25) 53 (67) .53
Hypertension 19 (24) 49 (62) .48
Hypertriglyceridemia 17 (21.5) 40 (50) .28
Low HDL 19 (24) 35 (44) .006a
Diabetes mellitus 12 (15) 17 (21.5) .02a
BMI 8 (10) 16 (20) .38
Anticoagulation 13 (16.5) 33 (42) .69
Atrial ﬁbrillation 2 (2.5) 10 (13) .38
CKD 4 (5) 17 (21.5) .35
Smoking 8 (10) 26 (33) .59
Alcohol use 3 (4) 6 (8) .63
BMI, Body mass index; CKD, chronic kidney disease; HDL, high-density
lipoprotein.
aStatistically signiﬁcant.
Fig. Kaplan-Meier survival analysis of survival after endovascular
aneurysm repair (EVAR). A, Survival of all patients. B, Survival of
patients with and without the metabolic syndrome (MetS). The
range bars show the standard error, which exceeds 10% at the
dotted line.
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the patients who had MetS and did or did not develop
endoleak, there was no difference in the rate of preopera-
tive anticoagulation or antiplatelet therapy (P ¼ .94).
Univariate and multivariate analyses are reported in
Tables IV and V, respectively. Low HDL was the only
MetS factor to show signiﬁcance.
Most of the type II endoleaks were observed during
the initial completion angiogram (Table VI). Of the 17
patients with initial type II endoleak, 16 had MetS
compared with only one patient without MetS. As such,
it is not surprising that of these 17 patients with initial
type II endoleak, all seven that resolved spontaneously
during follow up also had MetS; most of the 10 patients
who were monitored with persistent type II endoleaks
also had MetS. Two patients developed type II endoleaks
during surveillance, and both of those patients had MetS.
The endoleaks were detected on CTA surveillance at 3
and 6 months after EVAR, and both persisted throughout
follow-up without aneurysmal sac expansion.
Within the subgroup that had a type II endoleak, four
patients required reintervention for endoleak, but three of
these four patients were treated due to concomitant type Ior type III endoleaks as the primary indication for reinter-
vention. Lumbar collateral vessels were embolized in one
patient due to a signiﬁcant increase in aneurysmal sac size
caused by the type II endoleak.
DISCUSSION
We report that MetS is associated with the develop-
ment of type II endoleak after endovascular repair for
AAAs. Our reported rates of endoleak parallel those in
the literature, with most endoleaks being type II.13 The
need for secondary intervention was 100% for type I and
III endoleaks, as generally accepted in the literature and
clinical practice. Only one patient with type II endoleak
required embolization of collateral lumbar vessels for an
expanding aneurysmal sac. Although many of the type II
endoleaks were small leaks detectable at completion angio-
gram just after stent graft placement, a signiﬁcant number
of these endoleaks that persisted on follow up CTAs during
routine surveillance occurred in the MetS group.
We propose a “hyperdynamic circulation” as a causative
explanation for persistent ﬂow in the type II endoleaks
found in the MetS patients. MetS is a proinﬂammatory
state6 with associated endothelial dysfunction.14 In addi-
tion, MetS is typically associated with a prothrombotic
state. The myriad of systemic changes in these patients,
Table V. Logistic regression analysis of the metabolic
syndrome (MetS) factors for endoleak development
Factor OR (95% CI) P
Hypertension 2.1 (0.43-15.6) .37
Hypertriglyceridemia 1.1 (0.3-4.7) .88
Low HDL 6.3 (1.5-43.2) .0085a
Diabetes mellitus 2.7 (0.89-8.8) .08
BMI 1.5 (0.45-4.6) .52
BMI, Body mass index; CI, conﬁdence interval; HDL, high-density lipo-
protein; OR, odds ratio.
aStatistically signiﬁcant.
Table VI. Characterization of type II endoleak
Variable
All patients MetS Non-MetS
P(N ¼ 19) (n ¼ 18) (n ¼ 1)
At completion angiogram 17 16 1
Resolved 7 7 0 .013a
Persisted 10 9 1 .059
Developed 2 2 0 .55
MetS, Metabolic syndrome.
aStatistically signiﬁcant.
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release, nitric oxide upregulation, platelet dysfunction, and
atherogenic dyslipidemia, likely result in vascular pathology.
A splanchnic circulation or lumbar vasculature subjected
to these metabolic alterations, including hypertension
(Table III), could certainly be hyperdynamic and contribute
to persistent aneurysm sac ﬁlling.
Risk factors for type II endoleak are not completely
clear. The European Collaborators on Stent-Graft Tech-
niques for AAA and Thoracic Aortic Aneurysm and Dissec-
tion Repair (EUROSTAR) database showed multiple risk
factors, including older age, length of infrarenal aneurysm
neck, particular stent graft devices, preoperative coil embo-
lization of collaterals, smoking, and poor renal function
resulted in fewer type II endoleaks.15 More recently,
warfarin has been associated with an increased risk of
type II endoleak.16 Age, smoking, and anticoagulation
use were not associated with an increase in type II endoleak
in our study; however, with more use of antiplatelet agents
and anticoagulation in the MetS group, this is a possible
confounding factor despite the lack of statistical signiﬁ-
cance. No patients underwent preoperative embolization
of collaterals, and the various types of stent grafts were
not found to be signiﬁcantly different in rates of endoleak.
The presence of MetS in our patient population was
similar to those in other studies with a primary VA
cohort.10 That the VA patient population typically is high
risk (Fig, A) has been established,11 but various vascular
procedures can be performed safely in these patients.17
No differences were found between the groups for most
complications, and the overall complication rate was low.
AKI was signiﬁcantly higher in the MetS group. Although
this complication is most often attributed to baseline renal
reserve in conjunction with exposure to large amounts of
contrast during the EVAR procedure, it is an interesting
ﬁnding for two reasons. The ﬁrst is the proposed protective
effect of poor renal function to the development of type II
endoleak by the EUROSTAR data, which is different than
our ﬁndings. Second, this may indicate a group of patients
who deserve consideration for preoperative attempts at
renal protection such as intravenous hydration. This should
be investigated more thoroughly.
Study limitations include an all male, mostly Caucasian
cohort, with a relatively small number of patients. Thelimitations of a retrospective review are present. The debate
on the meaning of MetS and whether the true risk of this
syndrome lies with insulin resistance is ongoing. Mean-
while, the medical management of each component of
MetS has improved greatly just during the last decade.
It is also possible that patients with MetS might receive,
in some studies, different surveillance after EVAR if they
have different patterns of renal failure or BMI or waist
circumference, or both, biasing endoleak detection due
to a bias in imaging modality; however, nearly all of the
patients in this study were monitored with CT scans, mini-
mizing variations in surveillance between the groups.
Lastly, MetS includes a wide spectrum of abnormalities
ascribed to various genetic, dietary, and behavioral causes
and leading to a heterogeneous mixture of metabolic
abnormalities. The retrospective nature of this report
does not allow easy measurement of the speciﬁc effect of
each factor and certainly of the interactive effects among
them, including the level of control of each factor over
time.
The presence of MetS may be an indication for preop-
erative adjunctive maneuvers to prevent type II endoleak.
Ward et al18 recently demonstrated preoperative inferior
mesenteric artery embolization decreases the incidence of
type II endoleak as well as aneurysm sac enlargement up
to 24 months postprocedure. Lumbar embolization has
been demonstrated in the literature as well. Preoperative
intervention on aortic side branches, in particular the
lumbar vessels and mesenteric arteries, may provide
a protective effect against development and persistence of
type II endoleak in these MetS patients.
Finally, these patients may need closer surveillance with
more frequent imaging compared with their non-MetS
counterparts. A larger, prospective analysis would certainly
be helpful to assess the value of these interventions.CONCLUSIONS
MetS is associated with the development of endoleak,
in particular type II endoleaks, as well as with a trend to
persistent type II endoleaks. Whether these patients are
subjected to more intervention or morbidity and mortality
from these ﬁndings is unclear. However, increased atten-
tion, both preoperatively and postoperatively, to this
patient subset may be prudent.
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